CEO Viehbacher Confident In Biogen’s Portfolio, But Open To Additions

Q4 Revenue In Line, Guidance Below Consensus

 
• By Mandy Jackson
  
Biogen's Q4 sales were up 3% from Q4 2023, but full-year 2024 sales were down 2% (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Scrip